Can In-Licensing Models Substitute for Discovery?

Has a new biotech business model emerged for pure drug development companies, which start as corporate shells with top flight management teams and then proceed to in-license and further develop multiple products? While the business model is not new, clearly drug development is more fashionable today than drug discovery within the institutional investor community. The real question is whether the in-licensing model works any better than discovery.

Question: Has a new biotech business model emerged for pure drug development companies, which start as corporate shells with top flight management teams and then proceed to in-license and further develop multiple products?

Answer: While the business model is not new, clearly drug development is more fashionable today than drug discovery within the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.